Immutep (ASX:IMM) has announced that the investigator-initiated EFTISARC-NEO Phase 2 trial evaluating its eftilagimod alpha with radiotherapy plus MSD's KEYTRUDA (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.
Immutep’s efti combination meets primary endpoint in Phase 2 soft tissue sarcoma
May 26, 2025 Australian Biotech
Latest Video
New Stories
-
Australian company secures FDA approval to progress development of CAR-T therapy
June 16, 2025 - - Latest News -
These systems are and always have been more similar than most realise
June 16, 2025 - - Latest News -
Confirmation the UK has agreed to review medicine prices in response to US demand
June 16, 2025 - - Latest News -
Amplia says pathological complete response in patient from ACCENT trial
June 16, 2025 - - Australian Biotech -
This could be the canary in the coal mine, but a lot of canaries have already died
June 15, 2025 - - Latest News -
'There is a very real impact on Australian patients and clinicians'
June 15, 2025 - - Latest News -
Why not construct an off-ramp based on what you were going to do anyway?
June 15, 2025 - - Latest News